|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome.
|
30670777 |
2019 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
PTEN knockdown in thyroid cancer cell lines stabilized intracellular NIS protein by promoting an interaction with NIS-LARG (leukemia-associated RhoA guanine exchange factor).
|
30217930 |
2018 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels.
|
30086162 |
2018 |
|
Thyroid Neoplasm
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer.
|
29353884 |
2018 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
PPFP thyroid cancers have increased activation of AKT, and mice with thyroid-specific expression of PPFP combined with thyroid-specific loss of PTEN (a negative regulator of AKT) develop thyroid cancer.
|
29420754 |
2018 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The latter could explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent PTEN mutations and SDHx variants.
|
28164237 |
2017 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
At the present time, no study has been undertaken to consider thyroid cancer treatment via FOXOs and PTEN targeting.
|
26597586 |
2016 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in BRAF, NRAS, KRAS and PTEN, that are known to be involved in thyroid cancer biology, were detected in seven FNA samples.
|
24834793 |
2015 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Interestingly, KLLN-associated risk of thyroid cancer appears to be gender and PTEN status dependent.
|
25669429 |
2015 |
|
Thyroid Neoplasm
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We show that SRC inhibition could rescue SDHD dysfunction-induced cellular phenotype and tumorigenesis only when wild-type PTEN is expressed, in thyroid cancer lines.
|
25149476 |
2015 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Once a germline PTEN mutation is found, and a diagnosis of phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome made, the clinical outlook broadens to include higher lifetime risks for multiple cancers, beginning in childhood with thyroid cancer.
|
25916396 |
2015 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer.
|
26106610 |
2015 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
This was in contrast to patients with PTEN(mut+) who had thyroid cancer (0/39).
|
24712574 |
2014 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Other pathways like the PI3K/PTEN/AKT cascade are also active in many thyroid tumors.
|
24389136 |
2014 |
|
Thyroid Neoplasm
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our study shows that low blood PTEN protein expression could serve as a screening molecular correlate to predict for germline PTEN mutation in CS and CS-like presentations of thyroid cancer.
|
23066114 |
2012 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Here, we demonstrated a novel germline mutation in PTEN, as well as somatic loss of the wild-type PTEN allele in breast and thyroid tumors in a patient with Cowden syndrome.
|
23295304 |
2012 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Notably, individuals with SDH(var+) alone had the highest thyroid cancer prevalence (24/47) compared with PTEN(mut+) patients (27/105, P = 0.002) or PTEN(mut+)/SDH(var+) carriers (6/22, P = 0.038).
|
21979946 |
2012 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A total of 32 of 225 PTEN mutation+ patients (14%) had thyroid cancer: 52% papillary, 28% follicular-variant papillary, 14% follicular, and 6% anaplastic.
|
23158187 |
2012 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Children presenting with thyroid cancer should be tested for PTEN mutations.
|
21956414 |
2011 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
BEFREE |
Medical records, operative histology, and PTEN mutational analysis were reviewed to evaluate the pediatric presentation of PHTS-associated thyroid neoplasia.
|
20962022 |
2011 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-beta-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities.
|
19907326 |
2010 |
|
Thyroid Neoplasm
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells.
|
19173293 |
2009 |
|
Thyroid Neoplasm
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
The authors found an interesting association of PTEN methylation with the activating genetic alterations in the PI3K/AKT pathway in thyroid tumors.
|
18831514 |
2008 |
|
Thyroid Neoplasm
|
0.200 |
Biomarker
|
disease |
LHGDN |
ATP modulates PTEN subcellular localization in multiple cancer cell lines.
|
18579579 |
2008 |
|
Thyroid Neoplasm
|
0.200 |
GeneticVariation
|
disease |
LHGDN |
Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma.
|
18226854 |
2008 |